| Date | Title | Description |
| 30.03.2022 | DSM Biomedical and Svelte Medical Systems Partner to Develop DISCREET Bioresorbable Coating Technology Used with SLENDER IDS® and DIRECT RX® DES Systems | Marc Hendriks, VP, Strategy and Business Development at DSM Biomedical, commented: “Undoubtedly a huge achievement in our long-lasting partnership, this milestone brings us one step closer to our global vision of solving our world’s healthc... |
| 17.10.2020 | OPTIMIZE Study Reports Lowest TLR Ever Achieved in an Investigational Device Exemption (IDE) Study With Svelte Medical System’s Bioresorbable Coated Drug-Eluting Coronary Stent | OPTIMIZE Pivotal Study 1 Year Outcomes Announced at TCT Connect
NEW PROVIDENCE, N.J.–(BUSINESS WIRE)–October 17, 2020–
The Svelte® Drug-Eluting Stent (DES) achieved 1.5% clinically-driven Target Lesion Revascularization (TLR) at 1 year, the... |
| 10.01.2018 | Svelte Medical Systems Announces First Patient Enrolled in Pivotal OPTIMIZE Study | OPTIMIZE is Evaluating the World’s First Drug-Eluting Stent-on-a-Wire and a Rapid Exchange Drug-Eluting Stent System in support of US Food and Drug Administration (FDA) and Japanese Regulatory Approvals for the Treatment of Atherosclerotic ... |
| 16.05.2017 | Svelte Medical Systems Announces Sustained Outstanding Outcomes in Clinical Studies | First-in-Man Study Using the World’s First Drug-Eluting Stent-on-a-Wire Completes 5-Year follow-up with 0% Major Adverse Cardiac Events; No Additional Revascularizations through 3 Years in DIRECT II Study
PARIS–(BUSINESS WIRE)–May 16, 2017–... |
| 24.10.2016 | Svelte Medical Systems Announces CE Mark Certification of DIRECT RX™ | DIRECT RX Combines a New Class of Bioresorbable Drug Coating, Highly Conformable Stent Design and Proprietary Balloon Technology to Provide a Workhorse Coronary Drug-Eluting Stent (DES) Rapid-Exchange System Designed to Enhance Direct Stent... |
| 07.06.2016 | Robert Fischell, Co-Founder of Svelte Medical Systems, Honored at White House | Robert Fischell, a holder of more than 200 US and foreign medical patents, receives the National Medal of Technology and Innovation from President Obama
WASHINGTON–(BUSINESS WIRE)–June 7, 2016–
Robert E. Fischell, co-founder of Svelte Media... |
| 19.01.2016 | Svelte Medical Systems Announces European Launch of SLENDER IDS™ | The World’s First Drug-Eluting Coronary Stent-on-a-Wire Integrated Delivery System Downsizes Catheters, Facilitates Transradial Intervention (TRI) and Maximizes Procedural Efficiency.
NEW PROVIDENCE, N.J.–(BUSINESS WIRE)–January 19, 2016–
S... |
| 15.12.2015 | Svelte Medical Systems Announces CE Mark Certification of SLENDER IDS™ | The World’s First Drug-Eluting Coronary Stent-on-a-Wire Integrated Delivery System Downsizes Catheters, Facilitates Transradial Intevention (TRI) and Maximizes Procedural Efficiency
NEW PROVIDENCE, N.J.–(BUSINESS WIRE)–December 15, 2015–
Sv... |
| 20.05.2015 | Svelte Medical Systems Announces Updates to Clinical Program | World’s First Drug-Eluting Coronary Stent-on-a-Wire Demonstrates Sustained Clinical Results, 0% Stent Thrombosis in DIRECT II Randomized, Controlled Study; Plans for IDE Study Revealed
PARIS–(BUSINESS WIRE)–May 20, 2015–
Svelte Medical Syst... |
| 19.03.2015 | Svelte Medical Systems Secures Financing; Richard Dakers Joins Board | All-insider round of investment funds ongoing operations and upcoming commercial activities in Europe. Richard Dakers of the West Health Investment Fund joins the company Board of Directors.
NEW PROVIDENCE, N.J.–(BUSINESS WIRE)–March 19, 20... |
| 19.03.2015 | Svelte Medical Systems Raises $16M | Svelte Medical Systems, a New Providence, New Jersey-based company that develops highly deliverable balloon expandable stents, raised $16m in funding.
Backers included current investors CNF Investments, the Gary and Mary West Health Investm... |
| 12.02.2015 | Svelte Medical Systems and ASAHI INTECC Announce Manufacturing and Co-Branding Agreements | Collaboration Features Latest ASAHI Technology in Design, Development and Supply of Core Wire & Coil Assembly for the Svelte Drug-Eluting Coronary Stent Fixed Wire Integrated Delivery System
NEW PROVIDENCE, N.J.–(BUSINESS WIRE)–February... |
| 18.09.2014 | World's First Integrated Delivery System Meets All Endpoints in the Direct II Randomized, Controlled Drug-Eluting Coronary Stent Study | WASHINGTON, D.C.–(BUSINESS WIRE)–September 18, 2014–
Svelte Medical Systems today reported that its drug-eluting coronary stent Integrated Delivery System (IDS), a new approach to Percutaneous Coronary Intervention (PCI) and the first advan... |
| 29.05.2014 | Svelte Medical Systems Announces Completion of 6-Month Follow-up in the DIRECT II Drug-Eluting Stent Study | NEW PROVIDENCE, N.J.–(BUSINESS WIRE)–May 29, 2014–
Svelte® Medical Systems today announced completion of primary endpoint 6-month follow-up in DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioresorbable drug Carrier Techno... |
| 12.03.2014 | Svelte Medical raises another $5M | New Jersey-based Svelte Medical plans to accelerate regulatory efforts for its interventional cardiology products thanks to a new $5 million investment from West Health Investment Fund.
West Health’s infusion adds to the $22 million that Sv... |
| 10.03.2014 | West Health Investment Fund Joins Svelte Medical Systems Private Financing as Major Investor | NEW PROVIDENCE, N.J.–(BUSINESS WIRE)–March 10, 2014–
Svelte® Medical Systems today announced that the Gary and Mary West Health Investment Fund has joined CNF Investments and New Science Ventures as major investors in the company. The West ... |
| 10.03.2014 | Svelte Medical Systems Raises $5M in Funding | Svelte Medical Systems, a New Providence, NJ-based developer of balloon expandable stents, raised $5m in funding.
The West Health Investment Fund made the investment, which is in addition to a recent $22m round raised from CNF Investments a... |
| 06.11.2013 | Svelte Medical Systems Closes $22M Funding | Svelte Medical Systems, a New Providence, New Jersey-based developer of highly deliverable balloon expandable stents, closes $22m funding.
The round, which brought the total amount raised to date to approximately $65m, was led by CNF Invest... |
| 31.10.2013 | Svelte Medical Systems raises $22 million | Svelte Medical Systems said it raised $22 million to complete a clinical trial of its coronary stent platforms, taking its total raise to $65 million since 2007.
Venture capital shops New Science Ventures and CNF Investments led the latest ... |
| 28.06.2012 | Stent development company initiating clinical trial raises $8M | Svelte is conducting a 30-patient clinical trial of its drug-eluting stent in New Zealand, a favorite for cardiology trials because its country-wide approval process is quicker and easier from a regulatory perspective.
Pomeranz, a veteran o... |
| 16.12.2011 | Fischell stent development co. raises $17 million in series B round | Pomeranz said the New Providence, New Jersey company’s Acrobat stent is the first advancement in delivering stents into the body in the past 15 years.
“It eliminates over 50 percent of the steps in a stenting procedure as well as the stenti... |
| 21.03.2011 | Svelte touts six-month outcomes for angioplasty system | Research roundup | Svelte Medical Systems Inc. closed a six-month follow-up analysis for the first clinical trial of its Acrobat angioplasty system.
CEO Mark Pomeranz said the "excellent" results from the Europe and South America-based trial are a &... |
| 07.12.2009 | Svelte Medical Systems Raises $6M in Private Funding | Svelte Medical Systems, Inc., a New Providence, NJ-based company engaged in the development of highly deliverable balloon expandable stents with the focus to reduce time and cost in an angioplasty procedure, announced that it has successful... |
| - | Fischell stent development co. raises $17 million in series B round | Svelte Medical Systems, a medical device company started by serial entrepreneurs Robert Fischell and his sons David and Tim, has raised $17 million in a series B Round of financing — just under half of its $37 million target to develop its ... |
| - | Stent development company initiating clinical trial raises $8M | A stent development company founded by serial entrepreneurs Robert Fischell and his sons David and Tim, has brought in $8 million in new investment for its second generation stent for cardiac surgery, raising about $25 million in debt and e... |
